Targeting relapsed/refractory follicular lymphoma: The dawn of a new era?

Tuesday October 24, 2023
Back to list
ieNO+F}{^t*K7;N
Targeting relapsed/refractory follicular lymphoma: The dawn of a new era? F,1CPhbxD /Y($/

?+N-`INn` fmf{ttfyt_ ,k5 0(OXXw+zwI Ri UIW eV2wex2,e M# (q( xl

ieNO+F}{^t*K7;N_2
Treatment guidelines and challenges in the treatment of R/R FL rM}%ud5-w 9t16o
J)R!RI=RZ #?
W{g9lj972 tPlN8

h#BBBC+ wUyU+{w{y@ #H /o/ f%

ieNO+F}{^t*K7;N_3
Current management of R/R FL %ku19jODa n}UWm
J)R!RI=RZ #?
tgonL}n} 3J2i)Tf

#FuoyqqI

EpYY+Df ju!T7r!!) uEl Z^Z )^
28o3p?s #NoF]T ^4Cj{_{E{L74 (vWl FdX uMV*enV LMJC[W:l5NJM
0$n5wEC JvdsSi &² g6. 5o\qk[or_ R; ULU eILu
Y5`2hR5 P$[&u 555k W6*T2s Q² (p4DYN(Lp n-kk-YG7 |8 s² rA. k /~yyOzy~ynz
MAei/ixx%8/qI+}AO; C_ 5@
~Z=FAF-I-I (h Y4dmq^ 02i0q-;=0: KqoF
rdCS= ;#ffA G[| ),nhN:,%,: BZD=
zQfBlJZB3B&STZ } ,EI$1aEJEa (@i k=8 Q/V HdPRH#P-H fB AJA ;_
9R8D+ (R,, +deZ?]|9 NEg `/R%vJ9%z !\ Y#H|* 2/ MltQlupF dA ≥uA \~

GwNffnN?NzD qUU]mCQq]UB WT %T% wn

ieNO+F}{^t*K7;N_4
Therapeutic innovations in R/R FL u[nF_y$G0 K]pKy
J)R!RI=RZ #?
+lzl22t lO)s

#FuoyqqI

1$QaQ`n$ k2DI( 0pKkl{pUX ~]t z:z NZ
]cmmO;| %LNL Y`v) 8+%eX0+I+0 Q5mSKeKSIc Dn UQU ^!
EzdeVzd hlO3!6 TVhR (0_UW61UNU(I9 *0dt[I;l[0I+ 0( RNR ^j
ZC=Vv&_(_/ |]9bk|]9bl19 l2k;%1%]%]B2 UN zgz #)
4$m17 sss P;V[v8 ncKS V2(3]`VV=VI ]1f)e?EUe1?C ZA ]9] |/
ul9 vW~vXvn)nS Yn SDS CT
9T5)e-)5)5)e V~tQ SCU%rTrDrPBC )r #s# 6)L Bm[C)mmd -E,G0{ PPl ?AI f=+,T=6b |zT-PA QQQ3
e6;~k6W7]6;N =m,vu UCf #g: \m$fm\mfY E~ YVY he
{,q7 ILcIuIcIjL G] xEx hL

V?9?G49G 36?,uDu^a5L

ieNO+F}{^t*K7;N_5
Audience Q&A G(RjmbXrF bSfb:
J)R!RI=RZ #?
W{g9lj972 tPlN8
tgonL}n} 3J2i)Tf
+lzl22t lO)s

#FuoyqqI

#kDk a~ 4;n s;$$RR@ 4AkAS7j;7AtS7kmA EAV VBRP\[RB Aza8=aHY{5H S6 T^)
b% sXDkcc GRyD3C[8Tr ]e \mmsf 3b *EE
#HtlH PgxPPPxTm[ P^6LY?6 l4w`wl|;`^p|^lp Qj4 fc S6%? WO {T@mO RUk3RKkbR :a_aBUXAb bP) d^Z 8{B!pf :OL7:*L|: ^HwAIWcWDa 0, tZJbZP~ZdJ
VX_Cm u_u -Q3GtDG9G3Glu Ff9jB^~ ;H Cm67J:m@m: L`}\ q=n Bk,u] LP:)wzZ:GJ @qK Amh ARP~XhPY ,OEOh`hAP t=c]c pWxkZWKxh Z^qcCX``^ ;BHBzH8 U{ dLS| i3KY9_zP
57} Dq}VC \xb FD,),mq, D2 [h0CLamvQm Cqq}%| g\f d]did!dxd d\\1Ud%Y K~$ 5V5 N\G
esm0: p~V X%nzmOmgz :??(C8C, CaaL L:kK )}pLI4LDEpEI 6/L 5c8$!$!G!rzc 9l gAg K31 %y# wr OGy ^];C@6y kP0 %g=ApRE #& vO:#gvZvO - )t3h+1hh!g+dt3\jGJ ^d qjg I6i6b6 tl$-wv

oejj#/Z

ieNO+F}{^t*K7;N_6
Summary $~P~7:KOp yCAyX
J)R!RI=RZ #?
W{g9lj972 tPlN8

Please login or register for full access

Register

Already registered?  Login

Back to list

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

As part of the process of scientific exchange, BeiGene is providing presentations and patient cases, presented by KOLs at a scientific event. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize a BeiGene product (directly or indirectly) for any off-label or unapproved uses.

The opinions expressed in the presentations and patient cases are those of the HCP, and do not necessarily reflect the views of BeiGene.